Linden Advisors’s Oaktree Acquisition Corp III Life Sciences Warrant OACCW Stock Holding History

Linden Advisors’s Portfolio OACCW Stock Details OACCW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$127K	Hold	120,000	–	–	﹤0.01%	517
2026 Q1	$85.5K	Hold	120,000	–	–	﹤0.01%	476
2025 Q4	$99K	Hold	120,000	–	–	﹤0.01%	403
2025 Q3	$94.8K	Hold	120,000	–	–	﹤0.01%	349
2025 Q2	$105K	Hold	120,000	–	–	﹤0.01%	315
2025 Q1	$85.8K	Buy	+120,000	New	+$91.2K	﹤0.01%	245

Other funds holding OACCW

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DAM

Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BGGS

Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Linden Advisors's OACCW Position: Q2 2026 in Review

Linden Advisors held its Oaktree Acquisition Corp III Life Sciences Warrant (OACCW) position steady in Q2 2026 at 120,000 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #517.

Linden Advisors first reported a position in OACCW in Q1 2025 and has held it in 6 quarters since. 27 funds tracked by Wall St. Rank hold OACCW as of Q2 2026.

Linden Advisors held 120,000 shares of Oaktree Acquisition Corp III Life Sciences Warrant worth $127K as of Q2 2026.
Linden Advisors left its Oaktree Acquisition Corp III Life Sciences Warrant share count unchanged in Q2 2026.
Oaktree Acquisition Corp III Life Sciences Warrant made up ﹤0.01% of Linden Advisors's portfolio in Q2 2026, its #517 holding.
Linden Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences Warrant in Q1 2025 and has held it in 6 quarters since.
27 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Warrant as of Q2 2026.

Based on Linden Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.